Clinical Trial Update: Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update investigating talazoparib before standard therapy in invasive, BRCA-mutated breast cancer shows completed status with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Invasive Breast Carcinoma

Drugs mentioned

• Talazoparib (talazoparib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Breast Adenocarcinoma, Deleterious BRCA1 Gene Mutation | Phase 2 | Status: COMPLETED | Results posted: 2022-02-10